Kintampo Trial of Combination Therapy for Malaria
Malaria
About this trial
This is an interventional treatment trial for Malaria focused on measuring antimalarial drugs, efficacy, safety, trial
Eligibility Criteria
Inclusion Criteria: Age 6 months to 10 years Body weight >5 kg Uncomplicated P. falciparum malaria Mono-infection with P. falciparum Asexual parasite density 2,000 to 200,000 parasites/µl Haemoglobin ≥7.0 g/dL Axillary temperature ≥37.5ºC or history of fever in preceding 24 hr Ability to tolerate oral therapy Residence in study area Exclusion Criteria: Haemoglobin <7.0 g/dL Leucocyte count: >15,000/µL G6PD deficiency Mixed malaria infections Danger signs (unable to drink; repeated vomiting; recent history of convulsions; lethargic or unconscious state; unable to stand up or to sit) and signs of severe malaria as defined by WHO Any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known HIV infection) Concomitant disease masking assessment of response, e.g. known or suspected hearing impairments
Sites / Locations
- Kintampo Health Research Centre